Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.
about
HIV infection and osteoporosisHIV infection and bone disease.Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.The protease inhibitors and HIV-associated bone loss.Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, SpainThe efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.Drug safety profile of integrase strand transfer inhibitors.Integrase Strand Transfer Inhibitors in HIV Therapy.Bone health and HIV in resource-limited settings: a scoping review.Protecting bone in long-term HIV positive patients receiving antiretrovirals.Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.Bone alterations associated with HIV.
P2860
Q26853139-B89571D1-BD33-4E90-9ABC-595F2B6BF198Q30249771-D64E71ED-7850-4773-A532-87C9ECDC6C03Q36282696-AB3840AF-1C27-4CAF-8880-BE814DE9F88CQ36818259-DA142EB8-D950-4C06-9D2D-CE15D0630BD7Q37098390-016AA0B0-92C3-4801-AB16-A51A8F05A07EQ37354871-8F8743CA-0059-44A7-8817-369411F71592Q38193524-6EFCD21F-9EFB-4DB1-BD7F-221FBDD81E5FQ38240974-7F30985F-866F-4ED0-8133-5F3529A84C76Q38792298-607030D1-786B-425A-999D-3C0724F2E860Q38836871-B00A287A-ECF2-484D-84FE-344BC8953FB4Q40695106-B2732F8F-792B-4158-AD78-DC8864BD004DQ41546697-4DCAF31A-1888-46A1-BFAF-2A7F4D4903EDQ41647237-8BC0BF00-F107-43F3-9F5B-0CCEE88BEA25Q42203594-0A7866CB-0263-485C-8196-524F53627DE1
P2860
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Bone mineral density in HIV pa ...... standard second line therapy.
@en
Bone mineral density in HIV pa ...... standard second line therapy.
@nl
type
label
Bone mineral density in HIV pa ...... standard second line therapy.
@en
Bone mineral density in HIV pa ...... standard second line therapy.
@nl
prefLabel
Bone mineral density in HIV pa ...... standard second line therapy.
@en
Bone mineral density in HIV pa ...... standard second line therapy.
@nl
P2093
P2860
P50
P1433
P1476
Bone mineral density in HIV pa ...... standard second line therapy.
@en
P2093
Allison Martin
Cecilia Moore
David A Cooper
Patrick W G Mallon
Praphan Phanuphak
Samuel Ferret
Second Line study team
Waldo Belloso
P2860
P304
P356
10.1097/01.AIDS.0000432534.47217.B4
P407
P577
2013-09-01T00:00:00Z